Peer-Reviewed Research
AOD9604 is a modified peptide fragment derived from the C-terminal region of human growth hormone. Published research has examined lipid metabolism, fat oxidation, safety, metabolism, analytical detection, and cartilage-repair models. Recent AOD9604-specific primary research is limited, so this page includes recent reviews alongside older foundational studies.
Recent Review Articles
Therapeutic Peptides in Orthopaedics: Applications, Evidence, and Future Directions
Published: 2026
Study Type: Scientific review
Summary
This review discusses approved and investigational peptides used in orthopedic and regenerative research, including AOD9604. It evaluates proposed mechanisms, available experimental evidence, safety considerations, and gaps that remain before clinical applications can be established. This is a review article rather than a direct clinical study of AOD9604.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/41490200/
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
Published: 2026
Study Type: Narrative review
Summary
This publication reviews several approved and unapproved peptides marketed for musculoskeletal recovery and athletic performance, including AOD9604. It distinguishes proposed biological mechanisms from established clinical evidence and discusses regulatory status, safety concerns, and the limited quality of human data for many investigational compounds.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/41966639/
Peptides for Targeting Chondrogenic Induction and Cartilage Regeneration
Published: 2024
Study Type: Scientific review
Summary
This review examines peptides being investigated for cartilage targeting, chondrogenic signaling, and cartilage regeneration. Its discussion of AOD9604 is based largely on the rabbit osteoarthritis study summarized below and should not be interpreted as human clinical evidence.
Read Full Text:
https://pmc.ncbi.nlm.nih.gov/articles/PMC11556548/
Original Research
Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model
Journal: Annals of Clinical and Laboratory Science
Published: 2015
Study Type: Original preclinical animal research
Summary
Researchers evaluated ultrasound-guided intra-articular AOD9604, hyaluronic acid, or a combination of both in rabbits with collagenase-induced knee osteoarthritis. The study reported cartilage-regeneration findings, with the combined AOD9604 and hyaluronic-acid group producing stronger results than either intervention alone. These findings were obtained in a rabbit model and do not establish effectiveness in humans.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/26275694/
Read Publication:
https://www.annclinlabsci.org/content/45/4/426.abstract
Detection and in vitro metabolism of AOD9604
Journal: Drug Testing and Analysis
Published: 2015
Study Type: Original analytical and laboratory research
Summary
This study developed analytical methods for detecting AOD9604 and investigated its metabolism in vitro. Researchers identified metabolites relevant to peptide identification and anti-doping analysis. The study did not evaluate body composition, cartilage repair, or clinical effectiveness.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/25208511/
DOI:
https://doi.org/10.1002/dta.1715
Human Safety Research
Safety and Tolerability of the Hexadecapeptide AOD9604 in Humans
Journal: Journal of Endocrinology and Metabolism
Published: 2013
Study Type: Pooled analysis of human clinical safety data
Summary
This publication summarized safety and tolerability findings collected during earlier AOD9604 clinical-development studies. The authors reported that the observed safety profile was similar to placebo and did not show several adverse metabolic effects associated with full-length growth hormone. This publication primarily addresses safety and should not be interpreted as evidence of clinical effectiveness.
Read Full Publication:
https://jofem.org/index.php/jofem/article/view/157
DOI:
https://doi.org/10.4021/jem.v3i1-2.157
Safety and Metabolism of AOD9604, a Novel Nutraceutical Ingredient for Improved Metabolic Health
Journal: Journal of Endocrinology and Metabolism
Published: 2014
Study Type: Toxicology, pharmacokinetic, and metabolism research
Summary
This paper summarizes genotoxicity testing, chronic animal toxicology, tissue distribution, pharmacokinetics, and metabolism studies involving AOD9604. The reported findings did not identify genotoxic or major toxicological concerns in the experimental models studied. This publication does not establish human therapeutic effectiveness.
Read Full Publication:
https://www.jofem.org/index.php/jofem/article/view/213
DOI:
https://doi.org/10.14740/jem213w
Foundational Metabolic Research
Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone
Journal: Hormone Research
Published: 2000
Study Type: Original preclinical animal research
Summary
Researchers studied AOD9604 in obese Zucker rats and reported reduced cumulative weight gain and increased lipolytic activity in adipose tissue. This early animal study helped establish the metabolic rationale for later development, but it does not demonstrate equivalent outcomes in humans.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/11146367/
DOI:
https://doi.org/10.1159/000053183
Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
Journal: International Journal of Obesity and Related Metabolic Disorders
Published: 2001
Study Type: Original preclinical animal research
Summary
This study compared full-length human growth hormone with a modified C-terminal fragment in obese mice. Both treatments increased fat oxidation and reduced weight gain under the experimental conditions, while the fragment produced a different glucose and insulin profile from full-length growth hormone.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/11673763/
The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice
Journal: Endocrinology
Published: 2001
Study Type: Original preclinical mechanistic research
Summary
Researchers examined AOD9604 in obese mice and beta-3 adrenergic receptor knockout mice. The results suggested that beta-3 adrenergic signaling contributed to the peptide’s metabolic effects in the animal models studied.
View on PubMed:
https://pubmed.ncbi.nlm.nih.gov/11713213/
DOI:
https://doi.org/10.1210/endo.142.12.8522
Additional AOD9604 Publications
Browse current PubMed research:
https://pubmed.ncbi.nlm.nih.gov/?term=AOD9604
Research Disclaimer
The information presented in this Research Library is provided for educational and scientific reference purposes only and is based on published peer-reviewed research. Research findings continue to evolve, and investigational compounds may not be approved for clinical use. All Pearland Peptides products are supplied For Research Use Only and are not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease.